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Single nucleotide polymorphisms (SNPs) within the MIR137 gene locus have been shown to confer 
risk for schizophrenia through genome-wide association studies (GWAS). The expression levels of 
microRNA-137 (miR-137) and its validated gene targets have also been shown to be disrupted in 
several neuropsychiatric conditions, including schizophrenia. Regulation of miR-137 expression is 
thus imperative for normal neuronal functioning. We previously characterised an internal promoter 
domain within the MIR137 gene that contained a variable number tandem repeat (VNTR) 
polymorphism and could alter the in vitro levels of miR-137 in a stimulus-induced and allele-specific 
manner. We now demonstrate that haplotype tagging-SNP analysis linked the rs1625579 GWAS SNP 
for schizophrenia to this internal MIR137 promoter through a proxy SNP rs2660304 located at this 
domain. We postulated that the rs2660304 promoter SNP may act as predisposing factor for 
schizophrenia through altering the levels of miR-137 expression in a genotype-dependent manner. 
Reporter gene analysis of the internal MIR137 promoter containing the common VNTR variant 
demonstrated genotype-dependent differences in promoter activity with respect to rs2660304. In line 
with previous reports, the major allele of the rs2660304 proxy SNP, which has previously been linked 
with schizophrenia risk through genetic association, resulted in downregulation of reporter gene 
expression in a tissue culture model. The genetic influence of the rs2660304 proxy SNP on the 
transcriptional activity of the internal MIR137 promoter, and thus the levels of miR-137 expression, 
therefore offers a distinct regulatory mechanism to explain the functional significance of the 
rs1625579 GWAS SNP for schizophrenia risk.    
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MIR137 has been replicated as a strong schizophrenia candidate gene through genome-wide 
association1, 2. MIR137 encodes for miR-137, which has been identified as a modulator of processes 
implicated in schizophrenia pathogenesis including neurodevelopment, adult neurogenesis, 
synaptogenesis and neural transmission3-6. Other GWAS candidate genes for schizophrenia have 
also been validated as miR-137 targets1, 3, 7, 8, suggesting that dysregulation of the miR-137 pathway 
may be a key mechanism in neuropsychiatric dysfunction.  
 
We recently characterised an internal promoter within the MIR137 gene locus, which we termed 
Imir137, and validated its potential to modulate the levels of miR-137 expression in vitro using a 
reporter gene system9. The Imir137 promoter encompasses a variable number tandem repeat (VNTR) 
domain, which has previously been shown to modulate the processing and function of miR-137 in 
melanoma cell lines10. We demonstrated the ability of this polymorphic domain to modify the 
transcriptional activity of the Imir137 promoter in an allele-specific and stimulus-inducible manner9. 
Haplotype analysis of the MIR137 gene locus using genotype data from the HapMap CEU cohort 
showed that the MIR137 GWAS SNPs for schizophrenia were not in linkage disequilibrium (LD) with 
the MIR137 VNTR9. In this communication we show that the rs1625579 GWAS SNP does, however, 
tag the rs2660304 SNP located at the identified Imir137 promoter. Both rs1625579 and the rs2660304 
promoter SNP have been shown to modulate the levels of miR-137 expression11, 12. In this manuscript 
we propose a mechanism by which rs2660304 modulates miR-137 levels. 
 
  





Linkage disequilibrium (LD) analysis 
SNP genotype data spanning chromosome 1: 98,075,522-98,711,836 corresponding to individuals 
from the CEPH trios of European descent was downloaded from the HapMap Genome Browser 
(http://hapmap.ncbi.nlm.nih.gov/), release #28. Haplotype tagging SNP analysis was performed using 
Haploview 4.1 (www.broad.mit.edu/mpg/haploview/) under the Linkage Format feature (Hardy-
Weinberg p-value cut-off, 0.001; minimum genotype cut-off, 75%; maximum number of Mendel errors, 
1; minimum minor allele frequency, 0.01) and pair-wise tagging analysis performed (r2 threshold, 0.8). 
Haplotype blocks were determined using 95% confidence intervals13. 
 
HaploReg 
In order to annotate the potential regulatory effects of rs2660304 on transcription factor binding site 
motifs, the publically available HaploReg v3 software was employed (accessible at 
http://www.broadinstitute.org/mammals/haploreg/haploreg_v3.php). This calculates allele-specific 
changes in the log-odds (LOD) scores for position weight matrices (PWMs) of a regulatory motif 
based on TRANSFAC, JASPAR and PBM databases14. 
 
Plasmid Construction  
All MIR137 constructs used in this communication were cloned in the pGL3-Basic (pGL3B) luciferase 
reporter vector system (Promega). The Imir137 promoter construct containing the 4-copy variant of 
the MIR137 VNTR, termed Imir137(4), is described elsewhere9. Imir137(4) fragments plus an 
additional 69 bp of 5’ flanking sequence containing alternative alleles of the rs2660304 SNP were 
amplified using the following forward and reverse primers 5’-
ATACCTCGAGACCCAAGAATACCCGTCA-3’ and 5’-ATACACGCGTTCATACCACCTAGAGTGGAC-
3’ and cloned into the pGL3B vector at the XhoI and MluI restriction sites, respectively, indicated by 
the underlined sequences. The Imir137(4) constructs containing the major and minor alleles of the 








Cell Culture and Luciferase Reporter Gene Assays 
The human-derived SH-SY5Y neuroblastoma cell line (ATCC number CRL-2266) was maintained as 
described previously15. For luciferase assays, SH-SY5Y cells were seeded into 24-well plates at 
approximately 100 000 cells per well and transfected with 1 µg plasmid DNA and 10 ng pMLuc2 
(Novagen) (internal control for transfection efficiency) using TurboFect (Thermo Scientific). 
Transfected cells were processed 48 hours post-transfection using the Dual-Luciferase Reporter 
Assay System (Promega). Fold changes in firefly luciferase activity (normalized to renilla luciferase 
activity) supported by the Imir137 promoter domains over the pGL3B controls were calculated and 
significance determined using two-tailed t tests. Significance was scored as follows **/##P < 0.01, 
***/###P < 0.001. For each transfection, n = 4.     
  





Haplotype structure of the MIR137 Gene 
The functional significance of the previously identified rs1625579 GWAS SNP for schizophrenia 
located within the third intron of the MIR137 gene remains elusive. Pair-wise tagging SNP analysis 
using genotype data from the HapMap CEU cohort revealed that the intronic GWAS SNP rs1625579 
and a SNP rs2660304 situated 373 bp upstream of the precursor (pre)-miR-137 were in strong LD (r2 
= 0.96), figure 1. As previously reported the MIR137 VNTR was not found to be in LD with the GWAS 
SNP nor tagged by any other markers within the same haplotype blocks9. The rs2660304 proxy SNP 
therefore provided a distinct regulatory mechanism linking the GWAS variant to the Imir137 promoter, 
which can modify the levels of miR-137 based on VNTR copy number9. Figure 2 illustrates the 
position of rs2660304 in relation to the Imir137 promoter and the rs1625579 GWAS SNP. 
Evolutionary conservation over the MIR137 gene locus across multiple vertebrates is also depicted 
indicating strong mammalian conservation not only in exonic regions and the sequence 
encompassing MIR137 but also in intronic and intergenic regions, as determined by the height of 
peaks of sequence homology, figure 2. 
 
The major risk allele of rs2660304 downregulates Imir137 promoter activity 
The functional significance of rs2660304 was addressed using reporter gene constructs containing 
the common 4-copy variant of the Imir137 promoter VNTR. These constructs differed from the 
Imir137(4) construct previously reported9 by an extension to include 69 nucleotides containing the 
rs2660304 SNP, 5’ of the original promoter sequences analysed, and were termed Imir137(4)+A for 
the major allele and Imir137(4)+C for the minor allele (MAF; 0.168 in HapMap CEU), see figure 3A. 
Sequencing confirmed that these constructs varied only at the position of rs2660304. A significant 
difference in reporter gene activity was observed between the two alleles in SH-SY5Y cells (figure 
3B, ###p<0.001). The Imir137(4)+A construct containing the major allele of rs2660304 supported a 
1.32-fold reduction (###p<0.001) and 1.43-fold reduction (##p<0.01) in reporter gene activity relative 
to the minor allele Imir137(4)+C and the shorter construct Imir137(4), respectively, figure 3B. This 
genotype-dependent reduction in promoter function was consistent with previous studies showing that 
the major allele of rs2660304 is associated with downregulation of miR-137 expression11, 12. There 
was no significant difference in luciferase activity between Imir137(4) and the minor allele containing 




Imir137(4)+C construct (figure 3B), supporting the conclusion that the difference in expression 
directed by the Imir137(4)+A and Imir137(4)+C constructs was a function of the SNP as the extended 
fragments were otherwise identical.  
 
The potential regulatory function of the rs2660304 SNP on the Imir137 promoter was addressed using 
HaploReg v3, an online resource compiling information relating to epigenetic signatures, transcription 
factor binding sites, regulatory motifs and expression quantitative trait loci (eQTLs) relating to an 
expanded list of markers based on dbSNP-13714. Using this web-based tool, the presence of the 
major risk allele for the rs2660304 proxy SNP correlated with an increased PWM score for the p53 
transcription factor binding motif relative to the minor allele. Computational modelling of SNP-
associated changes in PWM scores for a discovered transcription factor binding site motif, such as 
p53 in this case, highlight regions of potential perturbation in the regulation of gene expression 
through altering transcription factor binding and alternative splicing. 
  





MIR137 has been identified as a gene that has a significant association with schizophrenia based on 
GWAS data1, 2. However the location of the associated SNPs within non-coding sequences suggests 
that the functional significance could be related to transcriptional or post-transcriptional regulation of 
the MIR137 gene. We have previously demonstrated the presence of a functional promoter in the 
region adjacent to the sequence of miR-137 itself and thus internal to the main precursor message9. 
This promoter contained a VNTR, the genotype of which could mediate differential reporter gene 
expression. This VNTR has a large number of variants in the HapMap CEU population and is not in 
LD with the previously identified MIR137 GWAS SNPs9, figure 1. However, haplotype analysis over 
the MIR137 locus showed strong LD (r2 = 0.96) between the schizophrenia-associated SNP 
rs1625579 with a SNP rs2660304 within the identified Imir137 promoter (figure 1 and 2). Absence of 
LD between these markers and the MIR137 VNTR which is flanked by the two SNPs is reflective of its 
highly polymorphic nature and compatible with this repetitive element mutating through 
recombination, as indicated by white regions of low D’ on the LD plot shown in figure 1. 
 
Due to the location of the rs1625579 GWAS SNP for schizophrenia within the first intron of the 
MIR137 gene, approximately 8.7 kb upstream of pre-miR-137, we postulated that the rs2660304 
promoter SNP located only 373 bp upstream of pre-miR-137 may act as a proxy for the GWAS SNP, 
representing an alternative regulatory mechanism for disease predisposition through direct 
modulation of the Imir137 promoter. Superimposed on the potential action of the GWAS proxy SNP in 
regulating miR-137 expression via the internal promoter, the MIR137 VNTR could further modulate 
this regulatory domain as we have previously demonstrated9. This was in part through the action of 
the transcription factor REST/NRSF (restrictive element-1 silencing transcription factor/neuron 
restrictive silencing factor). In addition, the MIR137 VNTR has previously been shown to affect the 
processing efficiency of miR-137 in melanoma cell lines, potentially through altering the secondary 
structure of the primary transcript in which it is located as determined by computational modelling10. 
This would support a gene-environment interaction (GxE) through which VNTR genotype could act 
mechanistically to influence disease phenotype through altering the levels of miR-137 from the 
GWAS-linked internal promoter. 
 




Analysis of the transcriptional potential of the promoter SNP using reporter gene constructs containing 
the common 4-copy variant of the MIR137 VNTR and the different alleles of rs2660304 showed allele-
specific regulation in SH-SY5Y neuroblastoma cells. The construct containing the major allele of 
rs2660304 (Imir137(4)+A) demonstrated reduced activity relative to the Imir137(4)+C minor allele 
construct. This difference in reporter gene activity was specific to the rs2660304 SNP as expression 
levels supported by the Imir137(4)+C (minor allele) construct, whose sequence is identical to 
Imir137(4)+A other than at the SNP, did not significantly differ from the shorter parental Imir137(4) 
construct (figure 3). The major allele of the rs1625579 GWAS SNP is defined as the risk variant for 
schizophrenia1, and has previously been associated with reduced miR-137 expression levels in post-
mortem brains of homozygous individuals relative to carriers of the minor non-risk allele11. The 
significant reduction in reporter gene activity supported by the promoter construct containing the 
major allele of rs2660304, a SNP that is in LD with the rs1625579 GWAS SNP for schizophrenia 
(figure 1), is consistent with the above in vivo finding and implicates this promoter SNP and the 
Imir137 promoter VNTR as a potential mechanism driving differential miR-137 expression. Recently a 
study found a genetic correlation between rs2660304 and endogenous MIR137 expression in human 
fibroblast-derived neuronal cells, which again supported lower levels of MIR137 in association with 
the major risk allele12. This study also addressed the transcriptional properties of this SNP but when 
directed by a heterologous minimal promoter in the pGL3 vector system and using a larger fragment 
encompassing both this SNP and the Imir137 promoter12; as such there could be confounding affects 
from having two transcriptional start sites in their construct. We have extended their analysis by 
demonstrating allele-specific expression of the rs2660304 SNP driven by its own internal promoter, 
Imir1379, figure 3B. The role of rs2660304 in the pathophysiology of schizophrenia is further 
supported by a recent study that reported a nominal genetic association of this SNP with this 
neuropsychiatric condition16, which strengthens its position as a proxy SNP for the rs1625579 
schizophrenia variant, figure 1. 
 
The rs1625579 GWAS SNP for schizophrenia has been reported to correlate with specific 
endophenotypes of the condition, with the major allele associating with cognitive deficits relating to 
working memory and executive function in individuals with negative symptoms; miR-137 expression 
levels; structural variations in the brain and earlier age of onset relative to carriers of the non-risk 




allele11, 17-19. Other studies have failed to identify such genetic correlations20, 21, suggesting that the 
functional significance of rs1625579 may be reflective of additive interactions between genetic 
variants within the MIR137 gene locus, other susceptibility loci and/or pathways modulated by miR-
137. This study was limited in that we did not address the synergistic effects of the rs2660304 proxy 
SNP with MIR137 VNTR copy number on Imir137 promoter function. Nor did we address the role of 
SNPs or INDELS within the MIR137 VNTR previously associated with modulating miR-137 expression 
levels in vitro4. Variants within promoter VNTRs may act as clinical correlates of disease through GxE 
mechanisms as demonstrated by the rs25531 SNP within the long allele of the 5-HTT-linked 
polymorphic region (5-HTTLPR), whereby the presence of the minor allele of this variant confers 
clinical phenotypes normally associated with the short ‘risk’ allele of 5-HTTLPR through modifying an 
AP2 transcription factor binding site 22, 23. In silico analysis of the potential regulatory effects of the 
rs2660304 SNP on promoter function identified a compositional change in the binding motif for the 
transcriptional regulator p53, indicating an increase in binding potential relative to the minor allele. 
p53 plays a crucial role in neurological development24 and has been shown to be modulated in 
response to neuronal damage both in vitro and in vivo, reviewed in 25. Genetic association has also 
implicated p53 in the pathogenesis of schizophrenia26, suggesting a potential regulatory network 
involving miR-137 and p53 as previously demonstrated in multiple myeloma cell lines27.  
 
In summary, the data presented in this study provides a direct regulatory mechanism for the genetic 
correlation of the rs1625579 GWAS SNP with miR-137 expression levels through the action of the 
rs2660304 proxy SNP, which we demonstrated can modulate allele-specific expression driven from 
the Imir137 promoter using a reporter gene system. The role of the rs2660304 SNP in regulating 
expression from the Imir137 promoter is distinct from the action of the MIR137 VNTR, which also 
influences allele-specific and stimulus-inducible expression from this regulatory domain, due to 
absence of LD between these two polymorphisms. Strong LD exists between the GWAS SNP 
rs1625579 and rs2660304 within the Imir137 promoter suggesting that these SNPs may flank an 
associated haplotype that confers risk for schizophrenia, which may include rare high copy number 
variants of the VNTR such as the 12-copy variant previously demonstrated in our reporter gene 
assays to be functionally distinct from the common 4-copy variant. The importance of these variants in 
disease predisposition may only be apparent at the level of GxE; the cellular response to which can 




be dynamically shaped by cell-specific or stimulus-induced activation of transcriptional and epigenetic 
regulators such as REST/NRSF shown previously by our group to be one such factor operating at this 
complex disease locus9. 
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Fig. 1. Linkage disequilibrium (LD) analysis of MIR137 gene locus. Haplotype block structure of the 
MIR137 gene based on squared correlation coefficient (r2) values calculated from 89 individuals from 
the CEPH collection of the International HapMap Project using the Linkage Format feature in 
Haploview 4.2  (Hardy-Weinberg p-value cut-off, 0.001; minimum genotype cut-off, 0.75; maximum 
number of Mendel errors, 1; minimum minor allele frequency, 0.01). SNPs spanning chromosome 1: 
98,075,522-98,711,836 were downloaded from the HapMap Genome Browser, release #28 
(http://hapmap.ncbi.nlm.nih.gov/index.html.en). Haplotype blocks, represented by a solid black 
triangular border, were determined using 95% confidence intervals proposed by Gabriel et al. (2002) 
which defined two haplotype blocks separated by the MIR137 VNTR which is located within a 
recombination hot spot represented by white squares. Pair-wise tagging SNP analysis (r2>0.8) 
revealed that the GWAS SNP rs1625579 and the MIR137 VNTR were not in LD. However, high LD 
(r2=0.96) was observed between rs1625579 and the internal MIR137 promoter SNP rs2660304, 
demarcated by a dashed triangular border. 
  










Fig. 2. Internal MIR137 promoter. Schematic showing the location of rs2660304 within the internal 
MIR137 (Imir137) promoter and its relation to the rs1625579 GWAS SNP. Highlighted region 
represents that targeted by PCR primers (labelled Imir137) for cloning into the pGL3-Basic luciferase 
vector system. Multiz Alignments of 100 Vertebrates displays measurements of evolutionary 
conservation using PHAST Package. Pairwise alignments of each species to the human genome are 
shown with peak height indicating higher levels of overall conservation. Double lines indicate one or 
more bases in the gap region that do not align to the reference genome suggesting excessive 
evolutionary distance between species; pale shaded regions represent lack of sequence data 
between the aligning species. Image taken from the UCSC Genome Browser, hg19: chr1:98501896-
98515504, accessed from http://genome.ucsc.edu/index.html. 
  


























Fig. 3. Functional analysis of the internal MIR137 promoter SNP rs2660304. (A) Schematic 
representation of the internal MIR137 promoter (Imir137) constructs containing the 4-copy VNTR, plus 
or minus the rs2660304 SNP. The Imir137(4) construct lacking rs2660304 differs from the 
Imir137(4)+A (major allele) and Imir137(4)+C (minor allele) constructs by 69 bp of sequence. (B) 
Luciferase activity supported by the Imir137 constructs in SH-SY5Y under basal conditions. N=4. 
*Significant changes in luciferase activity over backbone control. #Significant changes in luciferase 
activity between experimental conditions. ##p<0.01, ***/###p<0.001. 
 
